14 results about "Immunostimulant" patented technology

Provided is an adjuvant composition comprising a glycoarchaeol and at least one immunostimulant selected from a Toll-like receptor (TLR) agonist and a saponin. The glycoarchaeol and / or immunostimulant may be present as a pharmaceutically acceptable salt. The adjuvant composition may be comprised together with an antigen in an immunogenic composition, such as a vaccine composition, which may be for use to induce an immune response in a subject. Further provided is use of the immunogenic composition to induce an immune response in a subject, particularly an immune response that comprises both a cell-mediated response and a humoral response.

A hetero-structured RNA with two 3′-overhangs and use thereof as an immune stimulant are provided.

The present application provides an immunostimulant containing Lactobacillus helveticus, wherein the Lactobacillus helveticus has three functions: activation of dendritic cell-like cells, induction of immunoglobulin A (IgA) production, and induction of interleukin-12 (IL-12) production.

The present invention relates to a composition for enhancing immunity, comprising, as an active ingredient, an enzyme-treated product of polysaccharides derived from a mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora, or a novel purified fraction thereof. According to the present invention, the composition for enhancing immunity, comprising, as an active ingredient, an enzyme-treated product of polysaccharides from a mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora, or a novel purified fraction thereof, comprises specific types and contents of sugars. Thus, when macrophages, splenocytes, and NK cells are treated with the composition, the composition significantly increases the activities thereof, and therefore can be applied as an immunostimulant or a food composition for enhancing immunity.

Compositions containing a nucleic acid nanostructure having a desired geometric shape and immunostimulatory agent(s) bound to its surface are provided. The nanostructures can be, for example, in the form of a 6-helix bundle, or icosahedron, or a pentagonal bipyramid. The nanostructure design allows for control of the relative position and / or stoichiometry of the immunostimulatory agent(s) bound to its surface. The immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be a TLR agonist, such as a TLR9 agonist. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses, and for targeted induction of TLR activation are also provided.

The present application provides novel compounds or pharmaceutically acceptable salts thereof having TLR4 activating effects, and useful as immunostimulants or adjuvants in vaccine or allergen immunotherapy. The present application provides a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof. In the formula (I), X, Y, Z and n are each as defined in the specification.[Formula 1]

This invention relates to the field of vaccine adjuvant technology, and discloses an oil-in-water adjuvant containing squalene and α-tocopherol, its preparation method, and its application. The preparation method includes the following steps: mixing squalene, α-tocopherol, and poloxamer to obtain an oil phase mixture; subjecting the oil phase mixture to high-speed shearing with an aqueous phase to obtain a pre-emulsion; and subjecting the pre-emulsion to high-pressure homogenization to obtain the oil-in-water adjuvant. This invention, through the synergistic effect of α-tocopherol and poloxamer, combined with a specific preparation process, solves the problems of poor stability and uneven particle size distribution in existing adjuvants. The adjuvant prepared by this invention exhibits excellent long-term physicochemical stability, with a Z-average particle size in the range of 100-300 nm and a polydispersity index (PDI) of less than 0.25, demonstrating good immunostimulant carrying capacity and immune enhancement effect.

The present invention is directed to a method for treating cancer by delivering lipid-nanoparticles (LNPs) encapsulating immunostimulant mRNA and bispecific antibody mRNA to cancer cells or intratumorally. The method comprises the step of administering mRNA-encapsulated LNPs to a tumor lesion of a subject having cancer. The immunostimulant mRNA-LNP activates immune cells around tumor, which work together with mRNA-LNP encoding bispecific antibody and PBMC to effectively target local and distant metastatic tumors. Preferred immunostimulants are GM-CSF and IL-12, and its combination.

Compounds can specifically activate TLR7. The compounds are useful because they can stimulate innate immunity. The compounds can be used in the treatment of conditions including cancer, viral infections and skin lesions. The compounds can optionally be formulated for enhanced penetration following topical administration, the composition preferably initiating a local specific inflammatory cytokine response while limiting undesirable erythema and other inflammatory reactions. Pharmaceutical compositions contain the compound and preferably an additional compound such as imiquimod and / or resiquimod (R848). A composition contains the compound and a compound can be used as a medicament. Other aspects, embodiments, advantages and applications will become clear from the further description herein.

The application relates to the technical field of medicines, and particularly discloses a novel immune stimulant, a preparation method and application thereof. The immune stimulant comprises an alpha-mannose modified imidazoquinoline derivative, an N-acetyl cysteine modified cytosine-guanine dinucleotide, a glycyrrhetinic acid-polyethylene glycol derivative, a phytic acid-glycine oligomer, a medicinal excipient and water for injection, three modified active ingredients are bridged by the phytic acid-glycine oligomer as a bridging unit, and a ternary coordination complex is formed through dynamic non-covalent coordination. The preparation method comprises the following steps: after raw materials are pretreated, the active ingredients are premixed, dissolved and solvent is recovered, then dynamic coordination reaction, ultrafiltration purification and concentration are carried out, and finally, a finished product is obtained through double-cavity preparation forming. The immune stimulant can be used for preparing a tumor immunotherapy, an anti-infection treatment, an immune deficiency disease auxiliary treatment drug or a vaccine adjuvant, and has the advantages of high active ingredient stability, good in-vivo delivery efficiency and outstanding synergistic effect.

The application provides a cell preparation based on vaccine pre-sensitization and CpG coupling and a preparation method thereof, the cell preparation comprising immune cells subjected to sensitization treatment by a pre-sensitization vaccine and an immune stimulator CpG coupled to the surface of the immune cells after the sensitization treatment; wherein the pre-sensitization vaccine comprises a whole antigen engineering nanovesicle, the whole antigen engineering nanovesicle carries an agonist of an interferon gene stimulatory receptor inside, and the whole antigen engineering nanovesicle is derived from tumor cells. The CpG-loaded vaccine pre-sensitized T cells (CpG@VT) of the application can stimulate an anti-tumor immune cell promotion type reaction enhancement in a co-stimulation mode of effect T cell targeted delivery, direct killing and CpG-induced immunogenic death (ICD).

This invention utilizes an insect-baculovirus expression system to prepare the recombinant protein SADS-CoV-S of porcine acute diarrhea syndrome coronavirus, which is then used to prepare egg yolk antibodies. By optimizing the composition of the subunit vaccine composition for immunizing laying hens, IL-2 and ZnCl2 solution are added as immunostimulants to the conventional adjuvant, increasing the antibody concentration in the egg yolk antibody extract and improving the neutralizing antibody titer and protective efficacy. When IL-2 and zinc chloride aqueous solution are added to the immunization composition simultaneously, the resulting egg yolk antibody aqueous solution exhibits the highest protein concentration, and at the same protein concentration, the egg yolk antibody has the highest neutralizing titer. Compared to the immunization composition using Freund's complete adjuvant alone, the neutralizing titer is increased by more than 60 times.